Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Subsense secures $27M in seed funding to develop non-surgical brain-computer interfaces using nasally delivered nanoparticles.
PRIVATESep 03, 2026•4 days ago
Amount Raised
$27 Million
Round Type
Seed
Marina Del ReyBiotechnologyHealth CareMedicalMedical Device
Description
Subsense, a Palo Alto-based neurotechnology startup, announced a $27M seed funding round to advance its NanoBCI platform. The technology uses intranasally delivered nanoparticles combined with a wearable headset to read neural signals and stimulate brain activity without surgery. The company's immediate clinical targets include Parkinson's disease and epilepsy, with plans to demonstrate nanoparticle-enabled neural reading and symptom relief by the end of 2026. Founded around 2021-2022 by Tetiana Aleksandrova and Artem Sokolov, Subsense represents a novel approach to brain-computer interfaces.
Company Information
Company
Subsense
Location
Marina Del Rey, California, United States
About
Subsense, Inc. is a neurotechnology company developing the first non-surgical, nanoparticle-based bidirectional brain-computer interface. Subsense is partnered with leading global neurological research institutions.
The company is venture-backed with its global headquarters in Palo Alto, California. It is co-founded by neurotech entrepreneur Tetiana Aleksandrova and serial entrepreneur Artem Sokolov, who has been an early investor in companies that include: Asana, SoFi, Coursera, Lemonade, Digital Ocean among many others.
Don't miss Subsense's next move
Get an email the moment Subsense raises, hires an exec, or expands, usually minutes after it happens.
Marina Del ReyBiotechnologyHealth CareMedicalMedical Device